Chemical compound
 ;templatestyles src="Infobox drug/styles.css"/ ;
}}|[[Category:Infobox drug articles with contradicting parameter input| ]]}}{{#if:|{{#if:Investigational
 ||[[Category:Drugs with no legal status]]}}{{#if:{{#ifeq:{{lc:}} ||[[Category:Infobox drug articles without vaccine target]]}}{{#if: |[[Category:Drug has EMA link]]}}{{#if: |[[Category:Chemicals having QID set|*]]}}{{#if: |[[Category:Chemicals (indexed) having QID set|*]]}}{{#ifeq:|changed|[[Category:Drugboxes which contain changes to verified fields]]
}}{{#ifeq:|changed|[[Category:Drugboxes which contain changes to watched fields]]
Nelonemdaz is an experimental drug that works as a [[free radical]] reducer and selective antagonist of the [[GRIN2B|NMDA receptor 2b]]. It is hypothesized to have neuroprotective effects in people who recently experienced a [[stroke]].
References.
 ;templatestyles src="Reflist/styles.css" / ;
[[Category:NMDA receptor antagonists]]
[[Category:Experimental drugs]]
[[Category:Salicylates]]
[[Category:Fluoroarenes]]
[[Category:Trifluoromethyl compounds]]
[[Category:Anilines]]